Henry Schein (HSIC) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Illumina (ILMN) has outperformed Henry Schein (HSIC) over the past year, gaining 55.7% versus a gain of 13.8%. Over five years, HSIC leads with a +13.4% price change compared with -46.4% for ILMN. Illumina is the larger company by market cap ($29.15 billion vs $9.23 billion), about 3.2 times the size, while Henry Schein is growing revenue faster (+4.0% vs -0.7%).
On valuation, Henry Schein trades at a lower forward P/E (13.9x vs 31.2x for Illumina). Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSIC | ILMN |
|---|---|---|
| Share price | $83.52 | $192.82 |
| Market cap | $9.23B | $29.15B |
| 1-day change | -1.51% | -3.90% |
| YTD return | +10.51% | +47.01% |
| 1-year return | +13.79% | +55.69% |
| 5-year return | +13.42% | -46.40% |
| P/E ratio (TTM) | 22.88 | 33.19 |
| Forward P/E | 13.91 | 31.19 |
| EPS (TTM) | $3.65 | $5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.18B | $4.34B |
| Revenue growth (YoY) | +4.03% | -0.66% |
| Net income (latest FY) | $398.00M | $850.00M |
| Gross margin | 31.14% | 66.08% |
| Operating margin | 4.95% | 18.58% |
| Net margin | 3.02% | 19.57% |
| 52-week high | $92.18 | $309.35 |
| 52-week low | $68.70 | $112.65 |
| Distance from 52-week high | -9.39% | -37.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.98% | +35.59% |
| Average volume | 1.33M | 2.82M |
| Shares outstanding | 110.54M | 151.20M |
| Employees | 25,000 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Illumina is about 3.2 times larger than Henry Schein by market value ($29.15B vs $9.23B).
- ILMN has outperformed HSIC by 41.9 percentage points over the past year.
- Illumina trades at a higher earnings multiple (33.2x vs 22.9x trailing P/E).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 3.0 cents for Henry Schein.
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
HSIC vs ILMN FAQ
Which is bigger, Henry Schein or Illumina?
Illumina (ILMN) is larger, with a market capitalization of $29.15B compared with $9.23B for Henry Schein (HSIC).
Which stock has performed better over the past year, HSIC or ILMN?
ILMN returned +55.69% over the past 12 months, compared with +13.79% for HSIC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HSIC or ILMN?
HSIC has the lower trailing P/E at 22.9, versus 33.2 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Henry Schein and Illumina in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.